Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Beginning Cash Balance: 2021-2022

Historic Beginning Cash Balance for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to -$11.3 million.

  • Cardiol Therapeutics' Beginning Cash Balance fell 197.27% to -$11.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$11.3 million, marking a year-over-year decrease of 197.27%. This contributed to the annual value of $4.6 million for FY2024, which is 75.69% down from last year.
  • Per Cardiol Therapeutics' latest filing, its Beginning Cash Balance stood at -$11.3 million for Q3 2022, which was down 10.64% from -$10.2 million recorded in Q2 2022.
  • In the past 5 years, Cardiol Therapeutics' Beginning Cash Balance ranged from a high of $74.8 million in Q1 2022 and a low of -$11.3 million during Q3 2022.
  • In the last 2 years, Cardiol Therapeutics' Beginning Cash Balance had a median value of $11.6 million in 2021 and averaged $21.4 million.
  • The largest annual percentage gain for Cardiol Therapeutics' Beginning Cash Balance in the last 5 years was 2,280.88% (2022), contrasted with its biggest fall of 197.27% (2022).
  • Cardiol Therapeutics' Beginning Cash Balance (Quarterly) stood at $66.6 million in 2021, then slumped by 197.27% to -$11.3 million in 2022.
  • Its Beginning Cash Balance stands at -$11.3 million for Q3 2022, versus -$10.2 million for Q2 2022 and $74.8 million for Q1 2022.